Join to view full profile
22 S Greene StBaltimore, MD 21201
Phone+1 410-328-7157
Fax+1 410-328-6896
Dr. Kimball is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Maryland Medical Center2009
Sinai Hospital of BaltimoreResidency, Internal Medicine, 2006
University of Maryland School of MedicineClass of 2002
Certifications & Licensure
MD State Medical License 2009 - 2016
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2014
Clinical Trials
- Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma Start of enrollment: 2010 Apr 15
Publications & Presentations
PubMed
- Natural Killer T Cell Function in Lymphoma Patients.Roshanak Derakhshandeh, Michael S Lee, Yuyi Zhu, Emmanuel B Asiedu, Jocelyn Reader
Biomolecules. 2026-05-20 - 27 citationsPhase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas.Ajay Major, Justin Kline, Theodore Karrison, Paul A. S. Fishkin, Amy S. Kimball
Haematologica. 2021-07-29 - 8 citationsPhase 1b/2 study of ibrutinib and lenalidomide with dose-adjusted EPOCH-R in patients with relapsed/refractory diffuse large B-cell lymphoma.Wyndham H. Wilson, Tycel Phillips, Leslie Popplewell, Sven de Vos, Saurabh Chhabra
Leukemia & Lymphoma. 2021-04-15
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
